Ilyang awaits approval for ilaprazole in Korea

Ilyang Pharm is soon expecting to receive marketing approval for ilaprazole, a new investigational proton pump inhibitor, from the Korea Food and Drug Administration as the KFDA gave a nod on the safety and efficacy of the new drug after a stringent screening.

"Based on the pharmacokinetic profile observed in clinical trials, ilaprazole may have the potential to bring additional benefits to ...